Schrödinger, Inc. (SDGR)
| Market Cap | 1.07B -28.6% |
| Revenue (ttm) | 254.91M +10.6% |
| Net Income | -103.48M |
| EPS | -1.41 |
| Shares Out | 74.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,375,060 |
| Open | 15.85 |
| Previous Close | 15.85 |
| Day's Range | 14.23 - 15.85 |
| 52-Week Range | 10.95 - 27.63 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | 20.88 (+45.2%) |
| Earnings Date | May 5, 2026 |
About SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and cli... [Read more]
Financial Performance
In 2025, Schrödinger's revenue was $255.87 million, an increase of 23.29% compared to the previous year's $207.54 million. Losses were -$103.27 million, -44.81% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price target is $20.88, which is an increase of 45.20% from the latest price.
News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company's common s...
Schrödinger Transcript: RBC Capital Markets Global Healthcare Conference 2026
Biotech and pharma funding environments have improved, driving new customer growth and increased technology adoption. Early-stage computational tools and AI are accelerating drug discovery, with new products like Bunsen and predictive toxicology expected to boost license consumption and reduce late-stage failures.
Schrodinger price target lowered to $17 from $19 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Schrodinger (SDGR) to $17 from $19 and keeps an Equal Weight rating on the shares.
Schrödinger Transcript: Bank of America Global Healthcare Conference 2026
Q1 results exceeded guidance with broad-based growth, strong hosted revenue adoption, and disciplined expense management. Product innovation continues with predictive toxicology, LiveDesign Biologics, and Bunsen AI, while the transition to hosted solutions is on track. Nearly 100% customer retention and a robust track record support a positive outlook.
Schrödinger Earnings Call Transcript: Q1 2026
Q1 2026 saw 12% ACV growth and strong drug discovery revenue, with hosted software adoption accelerating and a major liquidity event from the Ajax Therapeutics acquisition. Guidance for 2026 remains robust, with continued investment in technology and a strong cash position.
Schrödinger Earnings release: Q1 2026
Schrödinger released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Schrödinger Quarterly report: Q1 2026
Schrödinger has published its Q1 2026 quarterly earnings report on May 5, 2026.
Schrödinger Slides: Q1 2026
Schrödinger has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Schrödinger Reports First Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. announced financial results for the quarter ended March 31, 2026.
Schrödinger to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in May: BofA Securities 2026 Healthcare Conference: Fireside c...
Schrödinger Proxy statement: Proxy filing
Schrödinger filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Schrödinger Proxy statement: Proxy filing
Schrödinger filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Schrödinger to Announce First Quarter 2026 Financial Results on May 5
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a con...
Schrodinger reports inducement grants under Nasdaq listing rule
Schrodinger (SDGR) reported that on April 16, the company granted restricted stock units with respect to 4,253 shares of the company’s common stock to four newly hired employees. These grants…
Schrodinger price target lowered to $20 from $25 at KeyBanc
KeyBanc lowered the firm’s price target on Schrodinger (SDGR) to $20 from $25 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup…
Schrödinger Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The forum highlighted a validated computational platform driving molecule design, a strategic shift to hosted software contracts, and a focus on early toxicity prediction with new products like Predictive Tox. AI integration and improved funding environments are expected to fuel growth and industry partnerships.
Schrodinger price target lowered to $13 from $18 at UBS
UBS analyst Michael Yee lowered the firm’s price target on Schrodinger (SDGR) to $13 from $18 and keeps a Neutral rating on the shares.
Schrödinger Transcript: Leerink Global Healthcare Conference 2026
The session detailed the transition to ACV for improved revenue visibility, highlighted robust partnership success, and addressed AI disruption concerns. New modules like predictive toxicology are set to drive growth, while materials science offers long-term potential.
Schrödinger Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a successful transition to hosted services, with ACV as the key metric, and showcased advances in computational chemistry and AI that are accelerating drug discovery. Growth is expected from predictive toxicology, expanded platform capabilities, and strategic partnerships, while the therapeutics pipeline progresses through collaborations.
Schrodinger price target lowered to $20 from $24 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on Schrodinger (SDGR) to $20 from $24 and keeps a Buy rating on the shares. While the firm views Schrodinger’s increased…
Schrodinger reports FY25 EPS ($1.41) vs. ($2.57) last year
Reports Q4 revenue $87.2M, consensus $83.7M. “Schrodinger’s (SDGR) performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our…
Schrödinger Earnings Call Transcript: Q4 2025
Revenue grew 23% to $256M in 2025, with strong software and drug discovery performance and a robust $402M cash position. Transition to hosted software is underway, targeting 10%-15% ACV growth and positive adjusted EBITDA by 2028, despite near-term revenue volatility.
Schrödinger Annual report: Q4 2025
Schrödinger has published its Q4 2025 annual report on February 25, 2026.
Schrödinger Earnings release: Q4 2025
Schrödinger released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Schrödinger Slides: Q4 2025
Schrödinger has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.